This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: RHHBY's Alzheimer's Study Failure, EU Nod for SNY's Enjaymo
by Kinjel Shah
Roche's (RHHBY) late-stage Alzheimer's disease study on key pipeline candidate, gantenerumab fails. Sanofi's (SNY) Enjaymo to treat a rare form of anemia gets approval in Europe.
The Zacks Analyst Blog Highlights Amazon, Sanofi, Target, Humana and PNC Financial Services
by Zacks Equity Research
Amazon, Sanofi, Target, Humana and PNC Financial Services are included in this Analyst Blog.
Sanofi (SNY), Regeneron Dupixent Gets CHMP Nod for Skin Disease
by Zacks Equity Research
The CHMP recommends approval of Sanofi's (SNY) Dupixent for the treatment of prurigo nodularis, a chronic inflammatory skin disease.
Top Stock Reports for Amazon.com, Sanofi & Target
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Sanofi (SNY) and Target Corporation (TGT).
Sanofi (SNY), GSK Receive EU Approval for COVID-19 Vaccine
by Zacks Equity Research
Sanofi (SNY) and partner GSK's COVID-19 vaccine receives authorization in the European Union for use as a booster in adults aged 18 years and older.
Pharma Stock Roundup: Q3 Earnings of BAYRY, AZN, EU Nod for AZN, SNY RSV Vaccine
by Kinjel Shah
Bayer (BAYRY) and AstraZeneca (AZN) announce third-quarter results. AstraZeneca and Sanofi's (SNY) RSV vaccine, nirsevimab gets approval in Europe.
Regeneron (REGN) Gets FDA Nod for Libtayo's Label Expansion
by Zacks Equity Research
Regeneron (REGN) obtains FDA approval for the second advanced NSCLC indication, which expands the patient population eligible for a Libtayo-based regimen to include combination treatment with chemotherapy, irrespective of PD-L1 expression levels.
Denali (DNLI) Lags Q3 Earnings Estimates, Pipeline in Focus
by Zacks Equity Research
Denali (DNLI) posts a wider Q3 loss. Collaboration revenues decline year over year.
Regeneron (REGN) Q3 Earnings & Sales Beat on Eylea, Dupixent
by Zacks Equity Research
Regeneron (REGN) tops earnings and sales estimates for the third quarter, driven by its lead drug Eylea and profits from the asthma drug, Dupixent. However, earnings decline year over year.
Regeneron (REGN) Q3 Earnings Coming Up: What's in the Cards?
by Zacks Equity Research
Regeneron's (REGN) third-quarter earnings are likely to have got a boost from the solid performance of Eylea and Dupixent.
Sanofi (SNY) Q3 Earnings Beat, Dupixent, Flu Jabs Push Sales
by Zacks Equity Research
Sanofi (SNY) beats third-quarter estimates for earnings and sales. Dupixent and flu vaccines drive sales growth. The company raises its earnings growth guidance for 2022.
BioMarin (BMRN) Q3 Earnings Beat, Sales Miss, Ups Voxzogo View
by Zacks Equity Research
BioMarin Pharmaceutical's (BMRN) third-quarter 2022 earnings beat estimates, but sales slightly miss the mark.
Sanofi (SNY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent and vaccines.
Sanofi (SNY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Sanofi (SNY) closed at $40.82, marking a +0.94% move from the previous day.
Sanofi (SNY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Sanofi (SNY) closed at $39.64, marking a -1.02% move from the previous day.
Regeneron (REGN) Drug Gets Positive CHMP View for Cervical Cancer
by Zacks Equity Research
Regeneron (REGN) gets a positive recommendation from CHMP for the label expansion of its oncology drug for treating adult patients with recurrent or metastatic cervical cancer.
Sanofi (SNY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Sanofi (SNY) closed at $39.92 in the latest trading session, marking a +1.73% move from the prior day.
Sanofi (SNY) Stock Moves -0.1%: What You Should Know
by Zacks Equity Research
In the latest trading session, Sanofi (SNY) closed at $38.86, marking a -0.1% move from the previous day.
Provention (PRVB) Up on Deal With Sanofi for Diabetes Drug
by Zacks Equity Research
Provention (PRVB) collaborates with Sanofi for the commercialization of lead investigational drug candidate teplizumab.
Will Seagen's (SGEN) Portfolio of Drugs Help Combat Rivalry?
by Zacks Equity Research
Seagen (SGEN) expects its portfolio of marketed drugs, which are approved for various cancer indications, to generate incremental sales and combat stiff competition.
Will Loss of REGEN-COV Sales Hurt Regeneron (REGN) in 2022?
by Zacks Equity Research
Regeneron's (REGN) top line is affected by negligible sales from REGEN-COV while lead drug Eylea faces stiff competition.
Sanofi (SNY) Relies on Dupixent and Vaccines to Drive Growth
by Zacks Equity Research
Dupixent has become the key top-line driver for Sanofi (SNY). Sanofi possesses a leading vaccine portfolio, which has become the primary top-line driver. Its R&D pipeline is strong.
Will Acquisitions Help Novo Nordisk (NVO) Combat Stiff Rivalry?
by Zacks Equity Research
Novo Nordisk (NVO) expects new acquisitions to diversify its portfolio of marketed drugs and help combat the stiff competition in the diabetes market.
BioMarin (BMRN) Refiles BLA With FDA for Hemophilia Gene Therapy
by Zacks Equity Research
If approved, BioMarin's (BMRN) valoctocogene roxaparvovec will be the first gene therapy for hemophilia A in the United States. The FDA filing also incorporates BMRN's responses to the CRL issued to the BLA in 2020.
Sarepta (SRPT) Seeks FDA Nod for DMD Gene Therapy Candidate
by Zacks Equity Research
If approved, Sarepta's (SRPT) SRP-9001 will be the first gene therapy for DMD indication in the United States. The company seeks approval for gene therapy under the accelerated pathway.